A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Cobimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Gastric cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 032
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Dec 2017 Planned End Date changed from 31 Dec 2018 to 23 Dec 2019.
    • 18 Oct 2017 Preliminary EuroQoL-5 Dimensions visual analog scale results from CheckMate 032 presented at the 18th World Conference on Lung Cancer
    • 17 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top